Biofrontera specializes in innovative therapies for dermatological conditions, particularly focusing on photodynamic therapy (PDT) for the treatment of non-melanoma skin cancers such as actinic keratosis and basal cell carcinoma. Over the past decade, the company has developed extensive expertise in PDT, which allows for the targeted removal of sun-induced skin damage while preserving healthy tissue. Their flagship drug, approved in both Europe and the USA, has undergone rigorous clinical trials to ensure its safety and efficacy, demonstrating a commitment to addressing the significant demand for effective treatments in dermatology. Biofrontera's approach includes not only treating visible lesions but also offering preventive therapies for early-stage skin conditions that may not yet be apparent.

In addition to its advancements in PDT, Biofrontera is expanding the applicability of its treatments beyond the head to include other sun-exposed areas of the body, such as the extremities, trunk, and neck. The introduction of daylight PDT allows for effective treatment in clinical settings with limited resources, and this method is now covered by public health insurance in Germany, broadening access to care. The company is dedicated to ongoing research aimed at optimizing PDT, with the goal of maximizing its therapeutic potential and facilitating its global adoption. Through a comprehensive understanding of the molecular basis of PDT and its clinical applications, Biofrontera is positioned to lead advancements in dermatological therapies.

Germany

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin.

Infectious Diseases

Skin Diseases

Biofrontera

Actinic keratosis

BF-RhodoLED® XL combo w/ Ameluz®

Basal cell carcinoma

Cancer

Skin cancer

Superficial basal cell carcinoma

Following topical application of 5-aminolaevulinic acid (ALA), the substance is metabolized to protoporphyrin IX, a photoactive compound which accumulates intracellularly in the treated actinic keratosis and basal cell carcinoma lesions. Protoporphyrin IX is activated by illumination with red light of a suitable wavelength and energy. In the presence of oxygen, reactive oxygen species are formed. The latter causes damage of cellular components and eventually destroys the target cells.

Ameluz (aminolevulinic acid hydrochloride) 

Bacterial infection

Impetigo

Methicillin-resistant staphylococcus aureus

The mechanism of action involves the inhibition of bacterial DNA replication enzymes, DNA gyrase A and topoisomerase IV. Ozenoxacin (XEPI) has been shown to be bactericidal against S. aureus and S. pyogenes organisms.

Biofrontera

Company Details